Biomedical Engineering Reference
In-Depth Information
11. Dobbin KK, Simon RM: Sample size planning for developing classifiers
using high dimensional DNA microarray data.
Biostatistics
8: 101-117,
2006.
12. Simon R, Radmacher MD, Dobbin K,
Pitfalls in the use of DNA
microarray data for diagnostic and prognostic classification.
et al.
J Natl
95: 14-18, 2003.
13. Hayes DF, Bast RC, Desch CE,
Cancer Inst
Tumor marker utility grading system:
a framework to evaluate clinical utility of tumor markers.
et al.
J Natl Cancer
88: 1456-1466, 1996.
14. Popovici V, Chen W, Gallas BG,
Inst
Effect of training sample size and
classification difficulty on the accuracy of genomic predictors.
et al.
Breast
12: R5 doi: 10.1186/bcr2468, 2010.
15. McShane LM, Altman DG, Sauerbrei W,
Cancer Res
Reporting recommendations
for tumor marker prognostic studies (REMARK).
et al.
J Natl Cancer Inst
97:
1180-1184, 2005.
16. Ball CA, Sherlock G, Parkinson H,
et al.
Standards for microarray data.
298: 539, 2002.
17. Cronin M, Pho M, Dutta D,
Science
Measurement of gene expression in
archival paraffin-embedded tissues: development and performance of
a 92-gene reverse transcriptase-polymerase chain reaction assay.
et al.
Am J
164: 35-42, 2004.
18. Cobleigh MA, Tabesh B, Bitterman P,
Pathol
Tumor gene expression and
prognosis in breast cancer patients with 10 or more positive lymph
nodes.
et al.
11: 8623-8631, 2005.
19. Paik S, Shak S, Tang G,
Clin Cancer Res
A multigene assay to predict recurrence
of tamoxifen-treated, node-negative breast cancer.
et al.
N Engl J Med
351:
2817-2826, 2004.
20. Fisher B, Jeong JH, Dignam J,
Findings from recent National
Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I
breast cancer.
et al.
J Natl Cancer Inst Monogr
(30): 62-66, 2001.
21. Habel LA, Shak S, Jacobs MK,
A population-based study of tumor
gene expression and risk of breast cancer death among lymph node-
negative patients.
et al.
Breast Cancer Res
8: R25 doi:10.1186/bcr1412,
2006.
22. Winer EP, Hudis C, Burstein HJ,
American Society of Clinical
Oncology technology assessment on the use of aromatase inhibitors as
adjuvant therapy for postmenopausal women with hormone receptor-
positive breast cancer: status report 2004.
et al.
J Clin Oncol
23: 619-629,
2005.
